grant
Neural mechanisms of psilocybin-assisted treatment for alcohol use disorder.
Organization NEW YORK UNIVERSITY SCHOOL OF MEDICINELocation NEW YORK, UNITED STATESPosted 1 Sept 2024Deadline 31 Aug 2029
NIHUS FederalResearch GrantFY20255-HT-2A Gene5-HT2A5-Hydroxytryptamine (Serotonin) Receptor 2A Gene5-Hydroxytryptamine Receptor 2A5-Hydroxytryptamine Receptor 2A GeneAfter CareAfter-TreatmentAftercareAgonistAlcohol DrinkingAlcohol consumptionAnimal ModelAnimal Models and Related StudiesAnxietyBOLD responseBehavioralBiological MarkersBlood SerumBrainBrain Nervous SystemCancersCharacteristicsChronic stressClinicalClinical ResearchClinical StudyControl GroupsCorpus StriatumCorpus striatum structureDataDiagnosticDoseDouble-Blind MethodDouble-Blind StudyDouble-BlindedDouble-Masked MethodDouble-Masked StudyDrugsEarly-Stage Clinical TrialsEmotionalEmotional DepressionEmotionsEncephalonEtOH drinkingEtOH useExhibitsExpectancyFunctional MRIFunctional Magnetic Resonance ImagingHTR2HTR2 GeneHTR2AHTR2A geneHallucinogenic AgentsHallucinogenic DrugsHallucinogenic SubstancesHallucinogensHeavy DrinkingIndividualInterventionLifeMachine LearningMajor Depressive DisorderMalignant NeoplasmsMalignant TumorMeasuresMedicationMental DepressionModelingMoodsNeuropsychologiesNeuropsychologyOutcomeParticipantPatient Self-ReportPatientsPersonsPharmaceutical PreparationsPhase 1 Clinical TrialsPhase I Clinical TrialsPhenotypePilot ProjectsPlacebosPrediction of Response to TherapyPsilocibinPsilocybinPsychedelic AgentsPsychedelicsPsychotomimetic AgentsPublicationsPublishingQuestionnairesROC AnalysesROC CurveRandomizedRandomized, Controlled TrialsRelapseResearchResidential TreatmentRestRodent ModelSamplingScientific PublicationSelf-ReportSerotonin 5-HT-2 Receptor GeneSerotonin 5-HT-2A ReceptorSerumSham TreatmentSocietiesSpecific qualifier valueSpecifiedStatistical MethodsStimulusStriate BodyStriatumSupportive TherapySupportive careTestingTherapeuticTimeTreatment outcomeVisualWorkalcohol abuse therapyalcohol abuse treatmentalcohol cravingalcohol cuealcohol ingestionalcohol intakealcohol product usealcohol related cuealcohol responsealcohol treatmentalcohol usealcohol use disorderalcoholic beverage consumptionalcoholic drink intakeanti-depressant effectantidepressant effectanxiety symptomsanxious symptombio-markersbiologic markerbiomarkerblood oxygenation level dependent responseclinical depressioncravingdepressiondepression modeldepression symptomdepressivedepressive modeldepressive symptomsdesigndesigningdrink heavilydrinkingdrinking behaviordrug/agenteffective therapyeffective treatmentemotion regulationemotional regulationemotional stimulusethanol consumptionethanol cravingethanol cueethanol drinkingethanol ingestionethanol intakeethanol product useethanol responseethanol useethanol use disorderexcessive alcohol consumptionexcessive alcohol ingestionexcessive alcohol intakeexcessive drinkingexcessive ethanol ingestionexecutive controlexecutive functionextreme drinkingfMRIheavy alcohol useimprovedincentive salienceinterestmachine based learningmajor depressionmajor depression disordermalignancymodel designmodel of animalnegative affectnegative affectivityneoplasm/cancerneuralneural controlneural mechanismneural regulationneuromechanismneuromodulationneuromodulatoryneuropsychologicneuroregulationnew drug targetnew druggable targetnew pharmacotherapy targetnew therapeutic targetnew therapy targetnovel drug targetnovel druggable targetnovel pharmacotherapy targetnovel therapeutic targetnovel therapy targetphase I protocolpilot studypost treatmentpre-clinical researchpreclinical researchpredict therapeutic responsepredict therapy responsepsychedelic drugpsychotomimetic drugrandomisationrandomizationrandomized control trialrandomly assignedreceiver operating characteristic analysesreceiver operating characteristic curveresidential careresponseresponse to alcoholresponse to ethanolsham therapysobersobrietystatistic methodsstriataltherapy predictiontreatment predictiontreatment response predictionvisual stimulus
Description preview
Preclinical and clinical research provides strong evidence that psilocybin and other 5-HT2A agonist/partial
agonist psychedelics have antiaddictive effects. In a double-blind randomized controlled trial of psilocybin-
assisted treatment for alcohol use disorder (AUD), administration of psilocybin resulted in robust decreases in
drinking which were…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click